Literature DB >> 30140959

Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk.

Katsuaki Yokoyama1, Shigemasa Tani2,3, Rei Matsuo1, Naoya Matsumoto1.   

Abstract

Hypertriglyceridemia, which often leads to both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) metabolic disorders, is a strong risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). We hypothesized that the triglyceride (TG)/HDL cholesterol (TG/HDL-C) ratio may be more useful for estimation of the LDL-particle size, as a well-known risk factor for ASCVD, as compared to the serum TG level per se. Polyacrylamide gel electrophoresis was used in this study to estimate the LDL-particle size [relative LDL migration (LDL-Rm value)] in 649 consecutive patients with one additional risk factor for ASCVD. Multivariable regression analysis identified both serum TG (β = 0.556, p < 0.0001) and the serum TG/HDL-C ratio (β = 0.607, p < 0.0001) as independent indicators of the LDL-particle size. In terms of evaluation of the accuracy of indicators of LDL-Rm values equal to or greater than 0.40, which are suggestive of the presence of large amounts of small-dense LDL and represent the upper limit (mean + 2 standard deviation) of the normal range in this population, both the serum TG level and serum TG/HDL-C ratio showed high accurate areas under the receiver-operating characteristic curve (0.900 vs. 0.914), but with a negative likelihood ratio of 0.506 vs. 0.039, indicating that the TG/HDL-C ratio model is superior for excluding patients with values below the cutoff value and with LDL-Rm values ≥ 0.40. Furthermore, in 456 patients followed up for at least 1 year, multivariable regression analysis identified increased serum TG/HDL-C ratio as an independent predictor of a decreased LDL-particle size. These results suggest that the serum TG/HDL-C ratio may be more useful for assessing the risk of ASCVD as compared to the serum TG level per se. To reduce the risk of ASCVD, it may be important to focus not only on changes of the serum LDL-C, but also on those of the serum TG/HDL-C ratio.

Entities:  

Keywords:  ASCVD; LDL-Rm value; LDL-particle size; TG/HDL-C ratio

Mesh:

Substances:

Year:  2018        PMID: 30140959     DOI: 10.1007/s00380-018-1247-9

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  34 in total

Review 1.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.

Authors:  P K Shah; S Kaul; J Nilsson; B Cercek
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

2.  Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?

Authors:  Tracey McLaughlin; Gerald Reaven; Fahim Abbasi; Cindy Lamendola; Mohammed Saad; David Waters; Joel Simon; Ronald M Krauss
Journal:  Am J Cardiol       Date:  2005-08-01       Impact factor: 2.778

3.  Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL.

Authors:  Takanari Nakano; Ikuo Inoue; Makoto Seo; Seiichiro Takahashi; Takuya Awata; Tsugikazu Komoda; Shigehiro Katayama
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2009-01

4.  Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.

Authors:  Shigemasa Tani; Michiaki Matsumoto; Ken Nagao; Atsushi Hirayama
Journal:  J Cardiol       Date:  2013-09-07       Impact factor: 3.159

5.  Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target?

Authors:  Arihiro Kiyosue
Journal:  J Cardiol       Date:  2017-10-13       Impact factor: 3.159

6.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

7.  Inflammatory and Cholesterol Risk in the FOURIER Trial.

Authors:  Erin A Bohula; Robert P Giugliano; Lawrence A Leiter; Subodh Verma; Jeong-Gun Park; Peter S Sever; Armando Lira Pineda; Narimon Honarpour; Huei Wang; Sabina A Murphy; Anthony Keech; Terje R Pedersen; Marc S Sabatine
Journal:  Circulation       Date:  2018-03-12       Impact factor: 29.690

8.  Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio.

Authors:  Martin R Salazar; Horacio A Carbajal; Walter G Espeche; Marcelo Aizpurúa; Pablo M Maciel; Gerald M Reaven
Journal:  Am J Med       Date:  2013-11-01       Impact factor: 4.965

9.  High-sensitivity C-reactive protein and white blood cell count equally predict development of the metabolic syndrome in a Japanese health screening population.

Authors:  Eiji Oda
Journal:  Acta Diabetol       Date:  2013-04-26       Impact factor: 4.280

10.  A cross-sectional and longitudinal study between association of n-3 polyunsaturated fatty acids derived from fish consumption and high-density lipoprotein heterogeneity.

Authors:  Shigemasa Tani; Rei Matsuo; Kenji Kawauchi; Tsukasa Yagi; Wataru Atsumi; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2017-11-20       Impact factor: 2.037

View more
  2 in total

1.  Association Between TG-to-HDL-C Ratio and In-Stent Stenosis Under Optical Coherence Tomography Guidance.

Authors:  Ya Li; Peng Jin; Fangjie Hou; Yujie Zhou
Journal:  J Med Syst       Date:  2018-11-20       Impact factor: 4.460

2.  The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting.

Authors:  Shigemasa Tani
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.